Hidradenitis Suppurativa (HS) Client Database Variables
Total Page：16
File Type：pdf, Size：1020Kb
1 Market Dynamix™: Hidradenitis Suppurativa (HS) Client Database Variables • Specialty (must be dermatology) • Years in practice (must be <2 or >40) • Geographic region of practice • Percentage of professional time spent in clinical practice (must be at least 50%) • Percent of patient visits related to medical dermatology conditions (must be at least 70%) • Number of patients with certain conditions (must treat at least 10 with HS) • Description of practice setting • Description of practice location • Total number of new vs returning patients with HS • Percent of physicians who participated in a clinical trial • Age groups of HS patients treated • Gender of HS patients treated • Ethnicities of HS patients treated • Unaided description of HS classifications • Percent of patients with: o Mild / Hurley Stage 1 HS, Moderate / Hurley Stage 2 HS, Severe / Hurley Stage 3 HS • Percent of time HS patient experienced a flare • Level of unmet need with treatment options for HS: o Mild / Hurley Stage 1 HS, Moderate / Hurley Stage 2 HS, Severe / Hurley Stage 3 HS • Percent of patients experiencing: o Optimal response, Good response, Moderate response, Poor response • Percent of adolescent patients (12-17) who are currently treated with therapies in each line of therapy: o Intralesional corticosteroid injections, Topical corticosteroids, Topical antibiotics, Systemic antibiotics, Systemic corticosteroids, Systemic immunomodulators, Retinoids, Humira, Off-label biologics/small molecules, Other (specify) • Percent of adult patients (18+) who are currently treated with therapies in each line of therapy: o Intralesional corticosteroid injections, Topical corticosteroids, Topical antibiotics, Systemic antibiotics, Systemic corticosteroids, Systemic immunomodulators, Retinoids, Humira, Off-label biologics/small molecules, Other (specify) • Percent ever prescribed off-label biologics/small molecules: o Enbrel, Remicade, Stelara, Cosentyx, Taltz, Siliq, Cimzia, Ilumya, Tremfya, Skyrizi, Dupixent, Other (specify) • Level of agreement with the following statements: o I only use surgery as a last resort, after an HS patient has failed all available options o HS patients are typically happy with treatment outcomes 2 o I always prescribe hormonal therapies to treat female HS patients between the ages of 18-45 • Level of importance with the following attributes: o Ability to titrate dosage o Can be used in adolescent patients o Can be used in patients with comorbidities o Convenient dosing schedule o Ease of obtaining insurance coverage o Effective in achieving partial response (50% skin clearance) o Effective in achieving total response (100% skin clearance) o FDA indication o Level of long-term safety o Mechanism of action o Mode of administration (i.e., topical, oral, injection) o Rapid response o Safe for women during pregnancy o Sustained efficacy o Other • Level of value on the following clinical endpoints: o Hidradenitis Suppurativa Clinical Response (HiSCR) o Physician's Global Assessment (PGA) o Disease Activity Score o Modified Sartorius Score o Change in count of abscesses and inflammatory nodules o Dermatology Life Quality Index (DLQI) o Proportion of participants at each category of Hurley Stage o Visual analog scale (VAS) for pain o Visual analog scale (VAS) for disease • Percent of patients treated with Humira who are: o Well managed, having a good response o Improving, but not optimal o Not having a great response o Recently initiated, still evaluating • Percent of patients not currently treated with Humira who are: o Not candidates for Humira, o Candidates for Humira but not currently prescribed o Previously prescribed Humira and failed • Percent of patients not using Humira for the following reasons: o Insurance coverage issues o Out of pocket costs o Lack of familiarity/comfort o Concerns about tolerability o Concerns about safety o Lack of manufacturer support o Poor prior experience o Patient adherence 3 o Concerns about efficacy o Patient reluctance o Narrow indication/ small patient population o Other o Insurance coverage issues o Out of pocket costs o Lack of familiarity/comfort o Concerns about tolerability o Concerns about safety o Lack of manufacturer support o Poor prior experience o Patient adherence o Concerns about efficacy o Patient reluctance o Narrow indication/ small patient population o Other • Percent of patients not using Humira for the primary reason of: o Insurance coverage issues o Out of pocket costs o Lack of familiarity/comfort o Concerns about tolerability o Concerns about safety o Lack of manufacturer support o Poor prior experience o Patient adherence • Percent of most recent adolescent/adult HS patients referred by: o Gynaecologist, Endocrinologist, Dermatologist, Primary Care Physician, Emergency Room Physician, Patient came directly to you / no referral, Other, do not know • If patient was referred: o Percent had preliminary HS diagnosis from referring physician at time of first visit with me o Percent had an incorrect diagnosis at time of first visit with me and I diagnosed HS o Percent not yet diagnosed, and I diagnosed HS • Tests use to diagnosed most recent adolescent/adult HS patient: o Biopsy, Trichoscopy/ dermoscopic imaging, Blood test (e.g. CBC), Bacterial culture, do not know, Other, no tests were used to diagnose HS (visual diagnosis only) • Percent of most recent patient with: o Mild / Hurley Stage 1 HS, Moderate / Hurley Stage 2 HS, Severe / Hurley Stage 3 HS • Age groups of most recent HS patients treated • Gender of most recent HS patients treated • Characterization of most recent adolescent/adult HS patient: 4 o Pain, Increased number of new lesions, Itchiness, Bleeding, Drainage, Increased scarring, Reduction of QOL • Rating of quality of life metrics for the most recent HS patient (Poor/severe impairment, Fair/moderate impairment, Good/minimal impairment, Excellent) o Social / leisure / family, Pain, Sexual activity, Fatigue, Sleep quality, Activities of daily living, Work/school performance, Mental health • Percent of time most recent HS patient experience symptoms before seeking care • Comorbidities experienced by most recent HS patient: o Anemia o Chronic pulmonary disorder o Depression / anxiety o Diabetes o Heart failure o Hypertension o History of, or current smoker o Hyperlipidemia/ Dyslipidemia o Obesity o PCOs o Thyroid disease o Venous thromboembolic events (VTE) o Other autoimmune conditions (specify) o Substance-related and addictive disorders o Cancer o Acne o Sleep/wake disorders o Sebaceous cysts o Hyperhidrosis o Other o No other comorbidities • Percent of most recent adolescent/adult patients who are currently treated with therapies: o Intralesional corticosteroid injections, Topical corticosteroids, Topical antibiotics, Systemic antibiotics, Systemic corticosteroids, Systemic immunomodulators, Retinoids, Humira, Off-label biologics/small molecules, Other (specify) • Satisfaction with response to treatment: o Satisfaction of treating dermatologist o Satisfaction of patient • Percent whose most recent patient experience flares in the past year • Length of time most recent patient experienced a flare • If had a flare, percent who combatted it by: o Adding to current treatment o Switching treatment/started new treatment o Other • Number of times most recent patient flared in the past year • Satisfaction with HS therapies: 5 o Intralesional corticosteroid injections, Topical corticosteroids, Topical antibiotics, Systemic antibiotics, Systemic corticosteroids, Systemic immunomodulators, Retinoids, Humira • Unaided awareness of therapies in development • Top MOAs: o IL-1 inhibitor, CD40 inhibitor, JAK-1 inhibitor, C5a antibody, IL-17 inhibitor, IL-23 inhibitor, IL-12/23 inhibitor, TNF inhibitor, TYK-2 inhibitor, PDE4 inhibitor • Familiarity with therapies in development: o Bermekimab/MABp1, a subcutaneous IL-1α inhibitor by Janssen/Biotech o Iscalimab/CFZ533, a subcutaneous CD40 inhibitor by Novartis o INCB054707, an oral JAK-1 inhibitor by Incyte o IFX-1, a C5a antibody by InflaRx o Cosentyx (secukinumab), a subcutaneous IL-17a inhibitor by Novartis o Bimekizumab, a subcutaneous and intravenous IL-17/IL-17F inhibitor by UCB o Skyrizi (risankizumab), a subcutaneous IL-23 inhibitor by AbbVie o Siliq (brodalumab), a subcutaneous IL-17 inhibitor by Valeant o Tremfya (guselkumab), a subcutaneous IL-23 inhibitor by Janssen o Avacopan, an oral complement C5a receptor antagonist by ChemoCentryx o LY3041658, an intravenous immunomodulator by Eli Lilly o Rinvoq (upadacitinib), an oral JAK-1 inhibitor by AbbVie o Otezla (apremilast), an oral PDE4 inhibitor by Amgen o PF-06650833, an oral IL-1 associated kinase inhibitor by Pfizer o Brepocitinib/PF-06700841, an oral JAK-1/TYK-2 inhibitor by Pfizer o PF-06826647, an oral TYK-2 inhibitor by Pfizer • If forced to choose one therapy to be approved, percent selecting: o Bermekimab/MABp1, a subcutaneous IL-1α inhibitor by Janssen/Biotech o Iscalimab/CFZ533, a subcutaneous CD40 inhibitor by Novartis o INCB054707, an oral JAK-1 inhibitor by Incyte o IFX-1, a C5a antibody by InflaRx o Cosentyx (secukinumab), a subcutaneous IL-17a inhibitor by Novartis o Bimekizumab, a subcutaneous and intravenous IL-17/IL-17F inhibitor by UCB o Skyrizi (risankizumab), a subcutaneous IL-23 inhibitor by AbbVie o Siliq (brodalumab), a subcutaneous IL-17 inhibitor by Valeant o Tremfya (guselkumab), a subcutaneous IL-23 inhibitor by Janssen o Avacopan, an oral complement C5a receptor antagonist by ChemoCentryx o LY3041658, an intravenous immunomodulator by Eli